New Strategies in Myelodysplastic Syndromes:  
Application of molecular diagnostics to clinical practice

Zuzana Tothova\textsuperscript{1,2}  
David P. Steensma\textsuperscript{2}  
Benjamin L. Ebert\textsuperscript{1,2}

\textsuperscript{1} Division of Hematology, Brigham and Women's Hospital, Boston, MA 02115  
\textsuperscript{2} Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215

Correspondence:  
Benjamin Ebert, MD, PhD  
Karp Family Research Laboratories, 5.211  
1 Blackfan Circle  
Boston, MA 02115  
Benjamin_Ebert@dfci.harvard.edu

Disclosures: Dr. Ebert has served as a consultant for Genoptix, Celgene, and Concert. Dr. Steensma has served as a consultant to Array Biopharma, Boehringer Ingelheim, and Genoptix.
ABSTRACT:

An increasingly complete compendium of recurrently mutated genes in myelodysplastic syndromes (MDS) has been defined, and the application of massively parallel sequencing to identify mutations in clinical practice now promises to improve the care of patients with this disease. More than 25 recurrent MDS-associated somatic mutations have been identified, involving biological pathways as diverse as chromatin remodeling and pre-mRNA splicing. Several of these mutations have been demonstrated to have prognostic implications that are independent of existing risk stratification systems based on clinical and pathological parameters. Application of these recent discoveries to diagnosis, prognosis, risk stratification and treatment selection for patients with MDS has the potential to improve patient outcomes. Here, we review recent advances in MDS and discuss potential applications of these discoveries to clinical practice.
BACKGROUND:

The myelodysplastic syndromes (MDS) comprise a clinically and pathologically heterogeneous group of hematologic neoplasms, collectively characterized by clonal hematopoiesis, aberrant myeloid differentiation, ineffective hematopoiesis leading to cytopenias, and a risk of progression to acute myeloid leukemia (AML)(1). The risk of developing MDS is increased both by exogenous factors, such as exposure to cytotoxic chemotherapy, radiation or benzene, and by inherited genetic predisposition, including that associated with congenital bone marrow failure disorders or several non-syndromic familial disorders that predispose to MDS/AML.

The diagnosis of MDS is based on persistent cytopenias in association with characteristic dysplastic findings in the peripheral blood (PB) and bone marrow (BM), excess blasts, or a cytogenetic or molecular marker proving clonality, as well as exclusion of other diseases(2). The 2008 World Health Organization (WHO) classification of hematologic neoplasms includes several MDS subtypes, defined by the proportion of blood and marrow blasts, the presence or absence of monocytosis or ring sideroblasts, cytogenetic findings, and the specific cell lineages involved by dysplasia(3). Despite the clinical utility of WHO subgrouping, significant heterogeneity in phenotype and outcome persists within WHO-defined MDS categories(4, 5) and there are also challenging cases where a diagnosis of MDS is possible but minimal diagnostic criteria are not met(6).

Because of wide variation in the clinical course of MDS, treatment algorithms for MDS rely heavily on accurate prognostic stratification. Investigators have made multiple attempts to incorporate clinical and pathological information into risk models for patients with MDS, in order to guide treatment recommendations. The International Prognostic Scoring System (IPSS), published in 1997, was developed to assess prognosis of untreated adult patients with primary MDS(7).
Since then, a number of other classification and prognostic scoring schemata have been developed with the goal of more accurately identifying disease subtypes with similar outcomes and risks of evolution to AML(8-12). Most recently, the revised IPSS (IPSS-R) defines five major prognostic categories based on five cytogenetic risk subgroups (including a broader range of karyotypic abnormalities than the original IPSS), BM blast percentage, and number and severity of cytopenias(4).

Clinicians currently tailor therapeutic recommendations to each patient’s situation, depending on the predicted risk of disease and the patient’s age, comorbid conditions, and functional status(13). Integration of somatic mutation assays into MDS diagnosis, risk stratification, and prediction of therapeutic response, has the potential to greatly improve treatment outcomes for this patient population. In addition, better understanding of the biologic basis of MDS will aid in the design of targeted, rationally designed novel therapies.

**ON THE HORIZON**

**Identification of Recurrent Somatic Mutations in MDS**

Genetic lesions that drive the phenotype of MDS contribute to enhanced or acquired self-renewal and impaired differentiation. Additional abnormalities in the BM microenvironment and in the epigenetic state of malignant cells may independently contribute to disease pathogenesis(14, 15). The compendium of genes with recurrent somatic mutations in MDS has grown dramatically over the last few years with the application of single nucleotide polymorphism (SNP) arrays, whole exome sequencing, and whole genome sequencing.

The genes mutated in MDS can be grouped into several categories: (1) transcription factors (e.g., TP53, RUNX1, ETV6)(16-18), (2) epigenetic regulators and chromatin remodeling factors (e.g., TET2, DNMT3A, ASXL1, IDH1/2, EZH2)(19-23), (3) pre-mRNA splicing factors (e.g., SF3B1, U2AF1, SRSF2)(24-
26), and (4) signaling molecules (e.g., NRAS, JAK2, NPM1)(16, 27) (summarized in Table 1). Over 70% of patients with MDS harbor somatic mutations or clonal cytogenetic abnormalities, and more than 50% of MDS patients carry at least one somatic mutation(28). Somatic mutations in SF3B1, TP53, TET2, and ASXL1 are among the most commonly identified changes, whereas those in TP53, EZH2, ETV6, RUNX1 and ASXL1 have been found to predict clinical phenotype and survival independent of other variables such as the IPSS score(16)(Table 1).

Similarly, a number of chromosomal aberrations, such as deletions of chromosomes 5q, 7 or 7q, Y, or 20q; trisomy 8; and recurrent translocations and inversions involving chromosome 3q, among others, have prognostic relevance (Table 2).

The phenotypic heterogeneity within MDS – as highlighted by the presence of variable number and severity of cytopenias, blast proportion, rate of progression to AML, response to treatment, and overall survival (OS) – is likely driven, to a great extent, by the specific pattern of these genetic changes and their interaction with therapeutic choices. Since many patients have several detectable genetic changes, it will be important to understand the interaction of these mutations with each other, as well as the impact of varying allele burden (i.e. degree of clonality) and its influence on the clinical phenotype.

**Decoding the Epigenetic Landscape of MDS**

Alteration in epigenetic mechanisms of regulation of gene expression are key drivers of malignant phenotype in different cancer types, including hematologic malignancies(29). Given the success of DNA methyltransferase inhibitors azacitidine and decitabine in the treatment of MDS, multiple studies have been undertaken to better define the epigenetic landscape of MDS, even though it is still unclear whether these agents exert their clinical effect entirely via DNA hypomethylation(30).
Promoter CpG island hypermethylation studies in MDS primary cells have identified widespread promoter hypermethylation of specific genes, including cell cycle and apoptosis regulators, and adhesion and motility genes, although the methylation status correlates poorly with treatment response(29). In addition, both MDS and AML have widespread promoter hypermethylation, with epigenetic deregulation of both cancer and non-cancer associated genes(31), which has also been linked to prognostic relevance(32, 33). It is still unclear whether abnormal methylation patterns are usually driven by somatic mutations that alter epigenetic state, such as the mutations in *DNMT3A, IDH1/2*, and *TET2* that affect DNA methylation status, or whether epigenetic abnormalities are themselves primary drivers of the disease in some cases.

**Moving Toward Improved Diagnostics**

The diagnostic evaluation of MDS has not changed significantly in the last 30 years and still relies on PB findings, morphologic evaluation and G-banded metaphase karyotyping of a BM sample(34). However, morphologic diagnosis of MDS remains challenging and often lacks inter-observer concurrence, with a 12% discordance rate among different pathologists with respect to diagnosing dysplasia, and even greater discrepancy when assigning a specific MDS subtype(35-37). Uncertainty about MDS diagnosis impairs prognostic assessment and therapeutic decision making.

The advent of multiparameter flow cytometry (MFC) in late 1980s improved identification and purification of different stem and progenitor cell populations within the context of both normal and malignant hematopoiesis. MDS cells often display an aberrant immunophenotype that can aid in their identification, and whereas standardization is still lacking and the optimal role of MFC in MDS diagnostics and risk stratification remains unclear(38, 39), addition of MFC to cytomorphology and cytogenetics can significantly increase diagnostic yield(40). MFC analysis of high- and low- risk MDS BM samples show differential expansion of stem and progenitor populations, which in turn correlate with
specific genetic, epigenetic and transcriptomic alterations(41). Additional studies of highly fractionated stem and progenitor compartments in MDS and understanding of their functional and clinical relevance remain active areas of research.

Identification of somatic mutations aids in diagnosis of uncertain cases of MDS and provides additional IPSS-independent information about prognosis. Therefore, testing for the presence of these mutations in PB or BM using deep sequencing is likely going to become routine, similar to our current practice of testing for \textit{JAK2} mutations or \textit{BCR/ABL} fusion in patients with myeloproliferative neoplasms. Given the remarkable advances in DNA sequencing technologies over the last few years and ever dropping costs, multiple platforms are now becoming widely available for mutational profiling in clinical practice(42). Although whole genome sequencing provides the most comprehensive analysis of somatic mutations, high cost and our lack of understanding of clinical relevance of non-coding DNA changes impede its adaptation into routine clinical practice at this time. Targeted sequencing, such as hybrid capture of selected exons or whole exome sequencing, can yield much higher coverage of relevant parts of the genome at a lower cost. Hybrid capture platforms currently offer excellent coverage at a reasonable cost and turnaround time (~ 2 weeks).

It remains to be determined whether the natural history of MDS diagnosed primarily on the basis of mutation testing has a similar natural history to MDS diagnosed using conventional criteria. The presence of an MDS-associated somatic mutation can at least confirm the presence of clonally-restricted hematopoiesis. For example, it has been shown that elderly individuals without any evidence of hematologic malignancy can acquire clonal hematopoiesis with recurrent somatic \textit{TET2} mutations(43). The contribution of such mutations to oncogenic transformation remains an area of active research.
Lastly, it is possible that a broad range of clinicians, including primary care providers, will eventually be able to evaluate their patients with new-onset cytopenias via PB testing for the presence of MDS-defining mutations, once a few common non-clonal causes of cytopenias such as nutritional deficiencies have been excluded. Having non-invasive option for diagnosis of MDS would be predicted to lower the threshold for testing and result in earlier identification of cases. Furthermore, although the initial diagnostic confirmation would most likely still involve a BM biopsy with a karyotype analysis even in patients with documented somatic mutations in their PB, serial repeat BM biopsies could become less critical for monitoring treatment response and disease progression.

**Moving Toward Improved Classification and Prognostication**

Multiple classification and prognostic scoring systems have been developed to identify MDS subtypes or risk groups with similar outcomes, as discussed above(4, 7-12). These schemes are based on morphology, clinical variables such as cytopenias, and cytogenetics. Somatic mutations are fundamental determinants of MDS pathophysiology, but are not part of any of the existing risk stratification systems.

Future classification and prognostic scoring systems may incorporate somatic mutations into existing models. Alternatively, new classification schemes and prognostic scoring systems may be developed that are fundamentally based on molecular abnormalities. If all mutations can be detected in PB by deep sequencing, it is possible that MDS could be diagnosed, classified and followed over time using PB without the need for repeat BM biopsies (Figure 1).

**Identification of Predictors of Response to Treatment**

MDS patients with interstitial deletions in the long arm of chromosome 5, in the absence of complex cytogenetics or TP53 mutations, demonstrate a striking response to treatment with the thalidomide derivative lenalidomide(44). In a Phase III randomized double blind study of lenalidomide in red blood cell (RBC)
transfusion dependent patients with low/intermediate-1-risk MDS with del(5q), treatment with lenalidomide resulted in RBC-transfusion independence in 56% patients, a cytogenetic response in 50% of patients, and increased OS with decreased risk of transformation to AML(45, 46). The exact mechanism of response is the subject of ongoing investigation.

Other than del(5q) for lenalidomide and serum erythropoietin levels predicting response to erythropoiesis-stimulating agents, there are no widely used biomarkers to aid clinicians in selection of therapy. Somatic mutations may serve as such biomarkers if they can be shown to consistently predict response to treatment. For example, in a recent Phase II study of lenalidomide and azacitidine in patients with IPSS intermediate-1, -2 and high risk MDS, the presence of TET2, DNMT3A, IDH1 or IDH2 mutations was predictive of achieving complete response, even in the presence of other somatic mutations that ordinarily carry a bad prognosis in MDS(47). In another retrospective study of 86 patients with MDS treated with azacitidine, the presence of a TET2 mutation was associated with an 82% response rate, compared to a 45% response rate in TET2 wild-type patients(48). Additional studies designed to identify genetic predictors of response to different treatment modalities, such as hypomethylating agents or stem cell transplantation, will be critical for tailoring appropriate therapy to each patient and minimizing toxicities from treatments with a low likelihood of therapeutic benefit.

**Monitoring Response to Treatment**

The ability to monitor treatment response via a non-invasive test would provide critical information to clinicians about ongoing therapeutic response and the development of resistance. Response to treatment would primarily be assessed by following the size of the malignant clone(s) over time compared to healthy cells, i.e., the percentage of cells bearing particular somatic mutations.
Next-generation sequencing studies have recently revealed and characterized the clonal architecture of MDS, and subsequent progression to secondary AML, in unprecedented detail. In the patients analyzed to date, more than 90% of the BM cells bore clonal somatic mutations at the time of MDS diagnosis, even among patients without excess blasts (49). The percentage of cells in the BM with somatic mutations does not increase significantly with progression from MDS to AML, but the genetics of the dominant clone do change. These results imply that clonal hematopoiesis involving majority of the BM is present even at early stages of MDS. Moreover, MDS is clearly a genetically complex disease, with multiple co-existing clones present in both MDS and AML, reflecting sequential acquisition of mutations and, in some cases, the parallel evolution of independent clones, some of which become extinct over time. With progression to secondary AML, the pre-existing MDS-founding clone always persists, though the MDS clone is outcompeted by more aggressive daughter subclones that drive the AML phenotype.

Ascertainment of the quantitative allele burden for different somatic mutations would be achieved by determining mutant allele frequencies (adjusted for chromosomal number) by means of deep sequencing of serial PB or BM samples. Since the size of each clone can be evaluated by the mutant frequency allele, mutant allele frequencies would delineate each subclone. Defining clonal heterogeneity of each patient at the time of diagnosis and with treatment will be instrumental in monitoring treatment response and early evidence of resistance and could result in much more timely change in treatment. The value of this approach will likely become apparent in prospective clinical trials.

Conclusions
Tremendous progress has been made in defining the genetic basis of myeloid malignancies, and MDS in particular. The identification of a growing compendium of recurrent genetic lesions in MDS and the development of technologies to track these mutations in a clinical setting have the potential to fundamentally alter the
approach to patients with MDS, from diagnosis, prognosis and risk stratification, and treatment. We envision that assays for clinically relevant somatic mutations will soon become part of routine evaluation of patients in clinic (Figure 1) as well as provide fertile ground for the development of novel therapeutic strategies for the treatment of MDS.

**ACKNOWLEDGMENTS**

This work was funded by the NIH (grants R01 HL082945 and P01 CA108631), the Leukemia and Lymphoma Society, and the Burroughs-Wellcome Fund.

**REFERENCES:**

associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia. 2010 May;24(5):1062-5.


35. Vardiman JW. Hematopathological concepts and controversies in the
diagnosis and classification of myelodysplastic syndromes. Hematology Am Soc
al. Implications of discrepancy in morphologic diagnosis of myelodysplastic
syndrome between referral and tertiary care centers. Blood. 2011 Oct
27;118(17):4690-3.
Comparison of referring and tertiary cancer center physician's diagnoses in
38. van de Loosdrecht AA, Westers TM, Westra AH, Drager AM, van der
Velden VH, Ossenkoppele GJ. Identification of distinct prognostic subgroups in
low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry.
cytometry in myelodysplastic syndromes: report from a working conference. Leuk
40. Kern W, Haferlach C, Schnittger S, Haferlach T. Clinical utility of
multiparameter flow cytometry in the diagnosis of 1013 patients with suspected
myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and
Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-
Sep 6;120(10):2076-86.
42. Metzker ML. Sequencing technologies - the next generation. Nat Rev
Z, et al. Recurrent somatic TET2 mutations in normal elderly individuals with
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen.
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N
M, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC
transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic
Phase 2 study of the lenalidomide and azacitidine combination in patients with
48. Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-
Rauzy O, et al. Impact of TET2 mutations on response rate to azacitidine in
Table 1: Summary of the currently known somatic mutations in MDS and their effect on overall survival.

<table>
<thead>
<tr>
<th>RNA Splicing</th>
<th>MDS (% cases)</th>
<th>MPN (% cases)</th>
<th>AML (% cases)</th>
<th>Effect on OS (MDS)</th>
<th>Independent risk predictor?</th>
</tr>
</thead>
<tbody>
<tr>
<td>SF3B1</td>
<td>14-28%</td>
<td>8%</td>
<td>rare</td>
<td>↓</td>
<td></td>
</tr>
<tr>
<td>SRSF2</td>
<td>6%</td>
<td>15%</td>
<td>rare</td>
<td>↓</td>
<td></td>
</tr>
<tr>
<td>ZRSR2</td>
<td>6%</td>
<td>1.3%</td>
<td>rare</td>
<td>←⇒</td>
<td></td>
</tr>
<tr>
<td>SF3A1</td>
<td>1.3%</td>
<td>1.3%</td>
<td>rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRPF40B</td>
<td>1.3%</td>
<td>&lt;1%</td>
<td>rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>U2AF65</td>
<td>&lt;1%</td>
<td>3%</td>
<td>rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SF1</td>
<td>1.3%</td>
<td>1.3%</td>
<td>rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRPF8</td>
<td>rare</td>
<td>rare</td>
<td>rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>LUC7L2</td>
<td>rare</td>
<td>rare</td>
<td>rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Epigenetic Regulators</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DNMT3A</td>
<td>10%</td>
<td>22%</td>
<td>14-24%</td>
<td>↓</td>
<td></td>
</tr>
<tr>
<td>TET2</td>
<td>19-26%</td>
<td>19-26%</td>
<td>14-24%</td>
<td>←⇒</td>
<td></td>
</tr>
<tr>
<td>EZH2</td>
<td>6%</td>
<td>&lt;1%</td>
<td>6%</td>
<td>↓</td>
<td>+</td>
</tr>
<tr>
<td>ATRX</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDH1/IDH2</td>
<td>4-12%</td>
<td>15-25%</td>
<td>14-24%</td>
<td>↓ (IDH1)</td>
<td></td>
</tr>
<tr>
<td>ASXL1</td>
<td>10-20%</td>
<td>10%</td>
<td>5-30%</td>
<td>↓</td>
<td>+</td>
</tr>
<tr>
<td>UTX</td>
<td>1%</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transcription Factors</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TP53</td>
<td>4-14%</td>
<td>4-14%</td>
<td>4-14%</td>
<td>↓</td>
<td>+</td>
</tr>
<tr>
<td>RUNX1</td>
<td>10-20%</td>
<td>12%</td>
<td>12%</td>
<td>↓</td>
<td>+</td>
</tr>
<tr>
<td>ETV6</td>
<td>1-3%</td>
<td>1-3%</td>
<td>1-3%</td>
<td>↓</td>
<td>+</td>
</tr>
<tr>
<td>WT1</td>
<td>rare</td>
<td>rare</td>
<td>rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHF6</td>
<td>rare</td>
<td>rare</td>
<td>rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Receptor Tyrosine Kinases/Signaling</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FLT3</td>
<td>2-3%</td>
<td>30%</td>
<td>30%</td>
<td>↓</td>
<td></td>
</tr>
<tr>
<td>c-KIT</td>
<td>1%</td>
<td>2%</td>
<td>2%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>JAK2</td>
<td>3%</td>
<td>50-95%</td>
<td>50-95%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBL</td>
<td>3%</td>
<td>3%</td>
<td>3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBLB</td>
<td>rare</td>
<td>rare</td>
<td>rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTPN11</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GNAS</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>KRAS</td>
<td>1-2%</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NRAS</td>
<td>10%</td>
<td>15%</td>
<td>15%</td>
<td>↓</td>
<td></td>
</tr>
<tr>
<td>CDKN2A</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>BRAF</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MPL, CSF1R</td>
<td>rare</td>
<td>rare</td>
<td>rare</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PTEN</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td>2-3%</td>
<td>&lt;1%</td>
<td>&lt;1%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MDS (myelodysplastic syndromes), MPN (myeloproliferative neoplasms), AML (acute myeloid leukemia), OS (overall survival), independent risk predictor (predictor of OS independent of IPSS score, age, and other mutations), ↑ (increased OS), ↓ (decreased OS), ←⇒ (no effect on OS), + (mutation determined to be an IPSS independent risk predictor based on multivariable analysis (16)).
Table 2: Summary of the most common chromosomal aberrations in MDS and their effect on overall survival

<table>
<thead>
<tr>
<th>Chromosomal Aberrations</th>
<th>MDS (% cases)</th>
<th>Effect on OS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Del(5q)</td>
<td>10-15%</td>
<td>↑</td>
</tr>
<tr>
<td>Monosomy 7, del 7q</td>
<td>10%</td>
<td>↓</td>
</tr>
<tr>
<td>Trisomy 8</td>
<td>8%</td>
<td>↔</td>
</tr>
<tr>
<td>t(3q), inv(3q)</td>
<td>&lt;5%</td>
<td>↓</td>
</tr>
<tr>
<td>i(17q)</td>
<td>rare</td>
<td>↔</td>
</tr>
<tr>
<td>Del(20q), Del(12p)</td>
<td>&lt;5%</td>
<td>↑</td>
</tr>
<tr>
<td>Del Y, Del(11q)</td>
<td>&lt;5%</td>
<td>↑↑</td>
</tr>
</tbody>
</table>

MDS (myelodysplastic syndromes), OS (overall survival), ↑ (increased OS), ↑↑ (significantly increased OS), ↓ (decreased OS), ↔ (no effect on OS)
Figure Legend

Figure 1: Proposed work-up of suspected MDS with incorporation of MDS-specific somatic mutation testing into clinical practice. Copy number evaluation is currently performed by cytogenetic analysis but will most likely be captured from sequencing data in the future.
Figure 1: Suspected MDS Somatic mutation testing

- Somatic mutation testing
- Bone marrow evaluation

- Treatment #2
- Adjust therapy
- Somatic mutation testing
- Copy number evaluation
- Monitor treatment response

- Diagnosis
- Prognostication
- Risk stratification
- Prediction of treatment response

Bone marrow evaluation
New Strategies in Myelodysplastic Syndromes: Application of molecular diagnostics to clinical practice

Zuzana Tothova, David P. Steensma and Benjamin L Ebert

Clin Cancer Res  Published OnlineFirst January 17, 2013.

Updated version  Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-12-1251

Author Manuscript  Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.